Xerecept corticotropin releasing factor: Discontinue Phase III enrollment

Celtic said it will discontinue enrollment in the double-blind, placebo-controlled, international Phase III NTI 0302 trial comparing Xerecept to dexamethasone due to slow enrollment and the expectatio...